Nutra Pharma Letter to Shareholders

CORAL SPRINGS, FL--(Marketwired - Dec 4, 2014) - Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the Company's Chief Executive Officer, Rik J Deitsch, has published a Shareholder Letter on the Company's website.

"We have had a very busy year at Nutra Pharma," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "2014 has been a watershed year for the company, bringing in our first significant sales in three years, launching our first new product in over two years (Pet Pain-Away) and allowing us to begin the first steps to get back into clinical research on our lead drug candidates," he continued. "I wanted to take this opportunity to update our shareholders and the public on the accomplishments of the year, the status of the Company and briefly outline our goals and expectations for the coming months," he concluded.

The letter includes some of the following accomplishments made by the Company over the past year:

• Began marketing and selling products through MyNyloxin.com Independent Entrepreneurs
• Brought all order processing and order fulfillment in-house to the Company's Plantation, Florida facility
• Created a marketing campaign for Nyloxin^® through the MyNyloxin Distributors that included, print, television and radio
• Filed for GSA Certification to Market Nyloxin^® and Military Strength Nyloxin^® to governmental agencies and the DoD
• Rolled out a national television campaign that included 30, 60 and 120 second spots (http://www.tinyurl.com/Nyloxinads)
• Began weekly radio promotions on Late Night Health Radio
• Began production of Pet Pain-Away, our first new product launch since 2010
• Completed upgrading our facilities and warehouse to accommodate the increased orders and prepare for the delivery of Pet Pain-Away
• Completed our Laboratory Recertification to go back to our roots of drug discovery and clinical development

The Shareholder Letter is available on the Company's website at: http://www.nutrapharma.com/Dec2014_shareholder_letter.pdf

About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin®. For additional information about Nutra Pharma, visit:
http://www.NutraPharma.com or
http://www.nyloxin.com

SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The publication of this Shareholder Letter should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.